Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis

Table 1 Patient demographics by first-line treatment n (%)

	First-line treatment									All newly treated patients
	SSA	CC	TT	SSA + CC	SSA + TT	TT + CC	IF	SSA + IF	SSA + TT + CC
n	13451	752	81	42	31	3	2	1	1	2258
	59.6%	33.3%	3.6%	1.9%	1.4%	0.1%	0.1%	0.0	0.0	100.0%
Age (mean ± SD, yr)	56.3 ± 9.5	54.7 ± 9.9	54.9 ± 10.5	53.5 ± 10.9	53.8 ± 10.1	59.3 ± 3.8	58.5 ± 3.5	N/A	N/A	55.6 ± 9.7
18-24	6 (0.4)	2 (0.3)	0 (0)	1 (2.4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	9 (0.4)
25-34	20 (1.5)	25 (3.3)	4 (4.9)	3 (7.1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	52 (2.3)
35-44	121 (9.0)	92 (12.2)	9 (11.1)	4 (9.5)	4 (12.9)	0 (0)	0 (0)	0 (0)	0 (0)	230 (10.2)
45-54	371 (27.6)	225 (29.9)	18 (22.2)	12 (28.6)	12 (38.7)	0 (0)	0 (0)	0 (0)	0 (0)	638 (28.3)
55-64	651 (48.4)	338 (44.9)	39 (48.1)	20 (47.6)	11 (35.5)	3 (100.0)	2 (100.0)	1 (100.0)	1 (100.0)	1066 (47.2)
65+	176 (13.1)	70 (9.3)	11 (13.6)	2 (4.8)	4 (12.9)	0 (0)	0 (0)	0 (0)	0 (0)	263 (11.6)
Female	677 (50.3)	341 (45.3)	40 (49.4)	26 (61.9)	17 (54.8)	1 (33.3)	1 (50.0)	0 (0.0)	0 (0.0)	1103 (48.8)
Region
Midwest	321 (23.9)	183 (24.3)	20 (24.7)	13 (31.0)	7 (22.6)	0 (0)	1 (50.0)	0 (0)	0 (0)	545 (24.1)
Northeast	261 (19.4)	150 (19.9)	12 (14.8)	11 (26.2)	7 (22.6)	1 (33.3)	0 (0)	0 (0)	0 (0)	442 (19.6)
South	563 (41.9)	323 (43.0)	36 (44.4)	12 (28.6)	15 (48.4)	2 (66.7)	1 (50.0)	0 (0)	1 (100.0)	953 (42.2)
West	200 (14.9)	96 (12.8)	13 (16.0)	6 (14.3)	2 (6.5)	0 (0)	0 (0)	1 (100.0)	0 (0)	318 (14.1)
Year of treatment initiation	130 (9.7)	41 (5.5)	4 (4.9)	2 (4.8)	1 (3.2)	0 (0)	0 (0)	1 (100.0)	0 (0)	179 (7.9)
2009
2010	271 (20.1)	122 (16.2)	4 (4.9)	11 (26.2)	7 (22.6)	0 (0)	1 (50.0)	0 (0)	0 (0)	416 (18.4)
2011	282 (21.0)	159 (21.1)	15 (18.5)	17 (40.5)	5 (16.1)	0 (0)	0 (0)	0 (0)	0 (0)	478 (21.2)
2012	270 (20.1)	168 (22.3)	33 (40.7)	4 (9.5)	10 (32.3)	0 (0)	1 (50.0)	0 (0)	1 (100.0)	487 (21.6)
2013	268 (19.9)	174 (23.1)	16 (19.8)	3 (7.1)	4 (12.9)	2 (66.7)	0 (0)	0 (0)	0 (0)	467 (20.7)
2014	124 (9.2)	88 (11.7)	9 (11.1)	5 (11.9)	4 (12.9)	1 (33.3)	0 (0)	0 (0)	0 (0)	231 (10.2)
Days of follow-up
Mean	621	514	454	588	425	244	675	836	496	576
(SD)	(468.5)	(409.1)	(403.6)	(424.1)	(269.6)	(140.7)	(145.7)	N/A	N/A	(447.1)
Median	500	393	290	455	360	216	675	836	496	454

¹964 with octreotide LAR, 380 with octreotide SA, and 1 with lanreotide. SSA: Somatostatin analogues; CC: Cytotoxic chemotherapy; TT: Targeted therapy; IF: Interferon.